Firms across the healthcare sector are working day and night to develop the first approved treatment for patients with Covid-19 — and, in the UK, BerGenBio looks to be a leading name in this particular race.
At the end of April, the Norwegian biotech company had its daily oral drug bemcentinib fast-tracked towards Phase II clinical trials by the government-funded ACCORD (Accelerating Covid-19 Research & Development platform) study.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
We take a closer look at the work BerGenBio has done to become one of the firms at the forefront of the UK’s hunt for an effective virus treatment.
